About casi pharmaceuticals - CASI
CASI Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing innovative therapeutics and pharmaceutical products. The firm is also involved in developing innovative therapeutics addressing cancer and other unmet medical needs for the global market. The company was founded in 1991 and is headquartered in Beijing, China.
CASI At a Glance
CASI Pharmaceuticals, Inc.
1701-1702, China Central Office
Beijing, Beijing 100025
| Phone | 86-10-6508-6063 | Revenue | 28.54M | |
| Industry | Pharmaceuticals: Major | Net Income | -39,258,000.00 | |
| Sector | Health Technology | Employees | 233 | |
| Fiscal Year-end | 12 / 2025 | |||
| View SEC Filings |
CASI Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 1.521 |
| Price to Book Ratio | 23.686 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -1.341 |
| Enterprise Value to Sales | 1.733 |
| Total Debt to Enterprise Value | 0.448 |
CASI Efficiency
| Revenue/Employee | 122,476.395 |
| Income Per Employee | -168,489.27 |
| Receivables Turnover | 1.86 |
| Total Asset Turnover | 0.443 |
CASI Liquidity
| Current Ratio | 1.086 |
| Quick Ratio | 0.942 |
| Cash Ratio | 0.441 |
CASI Profitability
| Gross Margin | 38.995 |
| Operating Margin | -137.415 |
| Pretax Margin | -133.402 |
| Net Margin | -137.569 |
| Return on Assets | -60.892 |
| Return on Equity | -301.799 |
| Return on Total Capital | -163.63 |
| Return on Invested Capital | -160.034 |
CASI Capital Structure
| Total Debt to Total Equity | 1,196.164 |
| Total Debt to Total Capital | 92.285 |
| Total Debt to Total Assets | 41.251 |
| Long-Term Debt to Equity | 136.953 |
| Long-Term Debt to Total Capital | 10.566 |